Phase I Clinical Trial Successful For An Aggressive Prostate Cancer Drug
There are so many treatments for prostate cancer but the options available for aggressive prostate cancer are limited.
However, there are ongoing research works for treatments that would readily tackle aggressive forms of prostate cancer.
One of these drugs is already passed the phase 1 of clinical trial, and it is hopeful it would soon scale other stages and get approval.
You may want to know how this drug works. That is important observation. The drug works by reducing the number of tumor cells and cancer markers present in cancer cells that are in the advanced stage.
Details of this new drug called Monomethyl Auristatin E MMAE have been posted online in an article titled “Phase 1 Success for New Prostate Cancer Drug” in dailyRx News November 29, 2012.
An excerpt from the article reveals how the Phase 1 clinical trial has been carried out. Details include: Daniel Petrylak, MD, current director of the Prostate Cancer Program/Genitourinary Cancer Program and co-director of the Signal Transduction Program at Yale University Medical Center, and his fellow scientists recruited 50 prostate cancer patients for this study.
Patients had the most advanced form of the disease—it had spread to the bones and organs. The subjects had received up to two prior chemotherapies and hormone therapy, but the cancer was still progressing.
Dr. Petrylak and his colleagues developed a medication that combined a cancer-destroying drug called monomethyl auristatin E (MMAE) with a targeting antibody that would help direct the medication to the cancer cells.
The antibody targets a protein on the cancer cells called prostate specific membrane antigen (PSMA). MMAE disrupts tubulins, the tiny molecules inside a cell that are essential for cell division. This combination of the antibody and the drug is called a PSMA antibody drug conjugate (PSMA ADC).
“By conjugating the antibody with a chemotherapeutic agent, we hoped that this would lead to more targeted therapy, which would have fewer toxic side-effects and would be more effective against the cancer,” said Dr. Petrylak.
The new drug was administered in three-week cycles for up to four treatment cycles. About half of the patients who received doses of at least 1.8 mg of the drug displayed signs of anti-tumor activity. They had a 50 percent or greater reduction in PSA levels, or a fall in Circulating Tumor Cells (CTC) in the blood to less than five cells per 7.5 ml of blood, or both.
Conclusively, more details of the study were presented at the 24th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Its also interesting to know that Progenics Pharmaceuticals Inc, are funders of the study. You can access more details from the dailyRX News article of November 29, 2012.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Enzalutamide Improves Survival for Castration- Resistant Prostate Cancer in Phase III Clinical Trial
- Prostate Cancer Treatment – First Clinical Trial for ValiRx’s VAL201 to Commence
- Clinical Trial Reveals Revlimid (Lenalidomide) Combination with Other Chemotherapy Drugs Fails as Prostate Cancer Therapy
- Prostate Cancer Clinical Trials – What You Should Know
- New Drug Derived From Poisonous Weed Treats Prostate Cancer
- Zytiga – New Prostate Cancer Drug From BTG
- Enzalutamide (MDV3100) – a New Drug from Medivation, can Increase Lifespan for Men with Terminal Prostate Cancer
- Prostate Cancer Clinical Trials – Understanding the Types and Phases
- New Drug KBU2046 To Contain Metastases of Prostate Cancer
- New Most Powerful Prostate Cancer Drug?
- Bayer New Prostate Cancer Drug
- Cancer Drug New Prostate – New Drug for Prostate Cancer
- Wake Forest Researchers Developing a Novel Drug for Prostate Cancer
- Prostate Cancer Drug Ban for NHS To Be Reversed By NICE
- Novel Drug Used on the Lockerbie Bomber Too Expensive for Prostate cancer Patients